US COVID-19 Update: Daily Roundup

▴ us-covid19-update-daily-roundup
The U.S. Food and Drug Administration recently continued to take action in the ongoing response effort to the COVID-19 pandemic:

The U.S. Food and Drug Administration recently continued to take action in the ongoing response effort to the COVID-19 pandemic:

The U.S. Food and Drug Administration authorized the first diagnostic test with the option of using home-collected saliva samples for COVID-19 testing. Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously authorized under the high complexity molecular-based LDT "umbrella" EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device. This announcement builds on last month's EUA for the first diagnostic test with a home-collection option, which uses a sample collected from the patient's nose with a nasal swab and saline.

FDA issued two documents designed to assist retail food establishments that might have been closed or partially closed during the COVID-19 pandemic in preparing to reopen. The checklist and infographic documents are designed to help businesses that prepare food to serve or sell to the public directly, such as restaurants, bakeries, bars and carry-outs, protect employee and public health as they reopen for business.

FDA issued an updated At-A-Glance that provides a quick look at facts, figures and highlights of agency's response efforts.

The FDA and Federal Trade Commission (FTC) issued warning letters to four companies for selling fraudulent COVID-19 products, as part of the agency's effort to protect consumers. There are currently no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.

The first seller warned, Sanit Technologies LLC dba Durisan, offers non-alcohol based hand sanitizer products for sale in the U.S. with false or misleading claims including that the products maintain their effectiveness for up to 24 hours. Such time-specific extended efficacy claims may give users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19.

The second seller warned, AgroTerra, Ltd. Dba Patriot Hemp Company, offers CBD products for sale U.S. with misleading claims that the products are safe and/or effective for the prevention of COVID-19. In addition, FDA observed that the company participates in the Amazon Associates program. In the program, the company earns commissions by promoting the sale of multiple products on the company's website with misleading claims that the products can mitigate, prevent, treat, diagnose, or cure COVID-19 in people.

The third seller warned, WashingtonsLastFrontier.Com, participates in the Amazon Associates program. As an Amazon associate, the company earns commissions by promoting the sale of products, including essential oils and dietary supplements, on the company's website with misleading claims that the products can mitigate, prevent, treat, diagnose, or cure COVID-19 in people.

The fourth seller warned, Chronic Lyme Treatments, offers herbal products for sale in the U.S. that misleadingly represent the products as safe and/or effective for the prevention and/or treatment of COVID-19.

Recently, the FDA issued an EUA for the Duke Decontamination System for use in decontaminating compatible N95 or N95-equivalent respirators for reuse by health care personnel when there are insufficient supplies of these respirators resulting from the COVID-19 pandemic. This is the sixth respirator decontamination system FDA has authorized for emergency use during this pandemic and the second based on public health emergency preparedness research funded by FDA.

FDA approved an Abbreviated New Drug Application for lidocaine hydrochloride injection USP, 1%, which is indicated for production of local or regional anesthesia and a drug listed in the FDA Drug Shortage Database. FDA recognizes the increased demand for certain products during the novel coronavirus pandemic and we remain deeply committed to facilitating access to medical products to help address critical needs of the American public.

Diagnostics update to date:
During the COVID-19 pandemic, the FDA has worked with more than 385 test developers who have said they will be submitting EUA requests to the FDA for tests that detect the virus.
To date, the FDA has issued 65 individual EUAs for test kit manufacturers and laboratories. In addition, 25 authorized tests have been added to the EUA letter of authorization for high complexity molecular-based laboratory developed tests (LDTs).

The FDA has been notified that more than 245 laboratories have begun testing under the policies set forth in our COVID-19 Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Guidance.
The FDA also continues to keep its COVID-19 Diagnostics FAQ up to date.

Tags : #USFDA #COVID-19 #Pandemic #Federaltradecommission

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024